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Zika virus infection was declared a public health emergency by the World Health Organization in 2016 
because of its rapidly expanding incidence 
and association with novel phenotypes, 
including sexual transmission and birth 
defects. As Zika and the closely related 
dengue viruses share the same mosquito 
vector, these viruses co-circulate in the 
same communities. Flaviviruses stimulate 
strongly cross-reactive immune responses 
in humans. Views of cross-reactive 
(heterologous) immunity in the flavivirus 
field are strongly coloured by the well-
supported hypothesis of antibody-
dependent enhancement, whereby non-
neutralizing, cross-reactive antibodies 
elicited by previous infection with a 
heterologous dengue serotype increase 
infectivity of Fc-receptor-bearing cells, 
leading to higher viraemia and greater risk 
for severe disease1. Although Zika virus is 
closely related to dengue, the extent and 
effects of immunologic cross-reactivity 
between Zika and dengue are unknown2.
Two recent publications3,4 from 
Sujan Shresta’s group at the La Jolla 
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Flaviviruses stimulate cross-reactive immune responses that may reduce or exacerbate manifestations of 
subsequent flavivirus infection. Recent work demonstrates that cross-reactive T cells protect against Zika in HLA 
transgenic mice, a key step in the development of safe and effective vaccines.
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Figure 1 | CD8+ T cell responses to Zika virus infection. a, Zika virus infection or vaccination elicits CD8+ T cells that are protective in some animal models. 
b, The epitopes targeted by Zika-reactive CD8+ T cells in humans are being identified. Zika-derived peptides presented by HLA can either be unique to Zika 
or conserved between Zika and closely related flaviviruses (blue represents peptide epitopes unique to Zika virus and red those conserved between Zika virus 
and dengue). c, How will existing dengue immunity affect T cell responses upon Zika infection? Dengue-virus-specific memory CD8+ T cells are unlikely to 
be activated by Zika exposure. Epitopes unique to Zika virus will prime Zika-specific naïve CD8+ T cells. Pre-existing cross-reactive memory T cells may be 
protective, ineffective, or disease enhancing. Wen et al. demonstrate a protective role for cross-reactive CD8+ T cells in HLA transgenic mice. ZIKV, Zika virus; 
DENV, dengue virus; IFN, interferon; TNF, tumour necrosis factor; IL, interleukin; GrzB, granzyme B, CTL, cytotoxic T lymphocyte.
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Institute of Allergy and Immunology, one 
of which appears in this issue of Nature 
Microbiology, use innovative mouse models 
to dissect the CD8+ T cell response to 
Zika virus (Fig. 1). CD8+ T cells mediate 
immunity to intracellular infections by 
recognizing and responding to specific 
peptides that are derived from intracellular 
proteins and presented on class I major 
histocompatibility complex (MHC) 
molecules. The role of CD8+ T cells in 
dengue pathogenesis is unclear: certain class 
I MHC haplotypes have been associated 
with increased or decreased rates of severe 
dengue5; however, these studies do not 
consistently include analysis of T cell 
function, along with human leukocyte 
antigen (HLA) typing. Earlier work 
suggested that cross-reactive T cell responses 
from prior dengue infection precipitate a 
dysfunctional profile of cytokine secretion 
and cytolysis by activated T cells6, but 
growing data indicate that individuals 
with more robust T cell immunity are 
less likely to develop symptoms or 
severe manifestations of homologous or 
heterologous dengue infection5.
As the mouse type I interferon 
response blocks the replication of Zika, 
Elong Ngono et al. used mice lacking the 
type I interferon receptor in a subset of 
myeloid cells as a model to study CD8+ 
T cell immunity to Zika4. In this model, 
the virus replicated and induced a robust 
CD8+ T cell response. Using transgenic mice 
lacking CD8+ T cells or passive transfer of 
CD8+ T cells from Zika-immune to naïve 
mice, CD8+ T cells were shown to reduce 
viral replication and ameliorate disease. 
These observations are similar to previous 
reports demonstrating that CD8+ T cells 
are protective in mouse models of dengue 
infection7,8. Collectively, these studies 
demonstrate that, in addition to the well-
established role of antibodies in protective 
immunity, CD8+ T cells also contribute to 
protective immunity against flaviviruses. 
A limitation of these studies is that the 
experiments must be carried out in mice 
with substantially altered immune systems 
in order to achieve productive flavivirus 
infection. Moreover, the specific viral 
epitopes targeted in mice are unlikely to be 
the same as in humans.
In this issue of Nature Microbiology, 
Wen et al. use type I interferon receptor-
deficient mice expressing human HLA 
proteins (HLA-B*0702 and HLA-A*0101) 
to identify Zika peptides that are likely to 
be targeted by human CD8+ T cells. Given 
the recent emergence of severe Zika cases 
in areas with endemic dengue transmission, 
many groups are now exploring whether 
dengue immunity modifies Zika disease or 
vice versa. Wen and colleagues also use the 
HLA transgenic mouse model to explore the 
role of prior dengue infection in shaping the 
T cell response to Zika infection.
What have we learned from Wen et al.? 
First, their data agree with other recent 
work in animal models of infection and 
vaccination showing that Zika virus elicits 
antigen-specific CD8+ T cell responses4,9–11. 
These T cell responses clearly have a 
protective role in the Shresta mouse 
model4, although they were not required 
for suppressing viraemia in a Balb/c mouse 
model of Zika vaccination11. Second, the 
HLA transgenic mouse model has previously 
demonstrated utility in identifying relevant 
epitopes targeted by human CD8+ T cell 
responses across a number of HLA alleles 
and viruses12. It is important to note that 
Wen et al. identified distinct epitopes 
compared to the Bl/6 mouse model4,9, 
further indicating that there are differences 
in determinants of immunodominance 
between species.
Wen et al. show that HLA transgenic 
mice infected with Zika or dengue 
develop CD8+ T cells that cross-react 
with several peptides that are conserved 
between Zika and dengue virus. They also 
demonstrate that dengue and Zika virus 
cross-reactive CD8+ T cell responses can 
be protective against Zika; however, this is 
not definitive proof that dengue infection 
will be protective against subsequent Zika 
infection in humans (Fig. 1c). Wen et al. 
used a computational method to predict 
the top class I MHC epitopes encoded by 
the Zika genome and tested these peptides 
for cross-reactivity. A more comprehensive 
(though less practical) approach to address 
this question would require screening 
for reactivity against all possible Zika-
derived peptide epitopes following dengue 
immunity. In fact, it may be that weakly 
cross-reactive T cell responses to Zika are 
the most problematic6, particularly if these 
come at the expense of more robust CD8+ 
T cell effector function or CD4+ T cell 
help for developing strongly neutralizing 
antibody responses.
Many unknowns remain, but through 
the identification of epitopes that are likely 
to be targeted by the human CD8+ T cell 
response to Zika, Wen et al. illuminate 
the way forward. Both Wen et al. and 
Elong Ngono et al. contribute to mounting 
evidence that T cells are critical players in 
immunity to flaviviruses and should be 
considered for vaccine development. Several 
dengue vaccines under development or in 
clinical trials do not include native antigens 
known to encode dominant T cell epitopes, 
and such approaches may need revisiting in 
view of the work discussed here. Validation 
of Zika epitopes recognized by CD8+ T cells 
from exposed human subjects is likely to 
follow soon. The HLA transgenic mouse 
system also provides an important tool 
for identification of CD8+ T cell epitopes 
that could quickly be translated into MHC 
class I tetramer reagents for tracking 
antigen-specific responses in humans and 
for performing mechanistic studies in this 
experimental model. ❐
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